查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1859227

過繼性細胞免疫療法市場報告：趨勢、預測和競爭分析（至2031年）

Adoptive Cellular Immunotherapy Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球過繼性細胞免疫療法市場前景廣闊，在醫院、癌症研究機構及其他市場均蘊藏著巨大機會。預計2025年至2031年間，全球過繼性細胞免疫療法市場將以23.1%的複合年成長率成長。推動該市場成長的關鍵因素包括：癌症發生率的不斷上升帶動了對過繼性細胞免疫療法的需求；細胞療法的進步提高了治療效果和預後；以及過繼性細胞免疫療法的高昂成本。

  • Lucintel預測，在預測期內，CAR-T細胞療法將是所有治療類型中成長最快的。
  • 按最終用途分類，預計醫院將實現最高成長。
  • 從區域來看，預計亞太地區在預測期內將達到最高成長。

過繼性細胞免疫療法市場的新趨勢

過繼性細胞免疫療法市場正在經歷幾個新興趨勢，這反映了細胞療法不斷擴大的潛力、改善患者預後以及擴大治療範圍。

  • 拓展至固體癌：儘管CAR-T療法在血液腫瘤治療中取得了巨大成功，但人們對將其應用拓展至固體癌的興趣日益濃厚。 CAR-T細胞標靶機制和修飾技術的進步，使得CAR-T細胞在治療乳癌、肺癌和卵巢等癌症方面更有效。這種拓展是重要的發展趨勢，將擴大過繼性細胞療法的影響範圍。
  • 個人化和精準醫療：過繼性細胞療法正成為個人化醫療的重要組成部分，其治療方案根據患者的個別基因譜量身定做。客製化治療，例如開發患者特異性CAR-T細胞，能夠提高治療效果並改善預後。這一趨勢正在革新癌症治療，為患者提供高度標靶和個人化的選擇。
  • 聯合治療：人們越來越關注將過繼性細胞免疫療法與其他治療方法，例如免疫查核點抑制劑、化療和標靶治療。這種策略旨在增強免疫反應、克服抗藥性機制並提高整體療效。聯合治療有望成為提高過繼性細胞免疫療法在多種癌症治療中成功率的重要促進因素。
  • 監管進展與核准：美國、中國和日本等主要市場的監管機構正在加速核准過繼性細胞免疫療法，尤其是CAR-T療法。簡化核准流程縮短了療法上市時間，使患者能夠更快地獲得治療。這些進展對於加速CAR-T療法的應用和推動市場成長至關重要。
  • 降低成本和提高可及性：過繼性細胞免疫療法的高昂價格一直是其面臨的主要挑戰。然而，目前各方正努力降低生產成本、提高擴充性並開發更經濟實惠的治療方法。降低生產成本將提高可及性，使更多患者，特別是印度和中國等開發中國家，能夠獲得這些先進治療方法。

過繼性細胞免疫療法市場正在湧現許多新興趨勢，包括拓展至固體癌、個人化醫療、聯合治療、不斷變化的監管環境以及成本降低，這些趨勢正在重塑癌症治療格局。這些趨勢提升了過繼性細胞療法為全球癌症患者提供更有效、更容易取得且更具針對性的治療方案的潛力。

近期過繼性細胞免疫療法市場趨勢

受技術創新、新的臨床試驗結果和監管部門核准，過繼性細胞免疫療法市場正經歷顯著的發展。這些進展正在擴大過繼性細胞療法的應用範圍，並提高其在治療各種癌症方面的療效。

  • FDA核准的CAR-T療法：在美國，Kymriah和Yescarta等CAR-T療法已核准用於治療白血病和淋巴瘤等血液癌症。這些核准為CAR-T療法進一步拓展至固體癌鋪平了道路。這些治療方法的成功推動了CAR-T細胞療法的應用，標誌著免疫療法市場的重大進展。
  • CAR-T細胞生產技術的進步：CAR-T細胞生產技術的創新正在提高生產的規模化能力、成本效益和速度。新的自動化技術有助於降低生產成本，從而解決過繼性細胞免疫療法面臨的關鍵挑戰之一。更有效率的生產將增加CAR-T療法的供應，使全球更多患者能夠獲得這些治療。
  • 臨床試驗的擴展：過繼性細胞免疫療法的臨床試驗正在包括美國、中國和印度在內的多個國家迅速擴展。這些試驗正在探索新的適應症和治療方法組合，使研究人員能夠評估 CAR-T 和 TIL 療法在更廣泛癌症類型中的療效。試驗數量的增加是推動市場成長和創新的關鍵因素。
  • 新興市場的監管核准：中國和日本等國家已簡化了過繼性細胞療法的監管核准流程，這正在加速這些地區的市場成長。監管機構正與生物技術公司密切合作，以確保創新治療方法的快速引入，從而增加CAR-T療法的可及性並擴大其市場。
  • 生物技術-製藥策略聯盟：生技公司與大型製藥企業之間的合作正在加速過繼性細胞免疫療法的開發和商業化。這些聯盟能夠共用資源、研究和專業知識，這對推進CAR-T細胞療法和其他細胞療法的臨床開發至關重要。這些聯盟在拓展市場方面發揮關鍵作用。

近年來，過繼性細胞免疫療法市場取得了一系列進展，包括獲得FDA核准、技術創新、擴大臨床試驗規模、獲得監管機構核准以及建立戰略合作夥伴關係，這些都推動了市場成長。這些進展使更多患者能夠受益於過繼性細胞療法，並有望徹底改變癌症治療模式。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章 全球過繼性細胞免疫療法市場（按類型分類）

  • 概述
  • 吸引力分析：按類型
  • CAR-T細胞療法：趨勢與預測（2019-2031）
  • NK細胞療法：趨勢與預測（2019-2031）
  • TIL療法：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031 年）

5. 全球過繼性細胞免疫療法市場（依最終用途分類）

  • 概述
  • 吸引力分析：依最終用途分類
  • 醫院：趨勢與預測（2019-2031）
  • 癌症研究所：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031 年）

第6章 區域分析

  • 概述
  • 全球過繼性細胞免疫療法市場（按地區分類）

7. 北美過繼性細胞免疫療法市場

  • 概述
  • 北美過繼性細胞免疫療法市場（按類型分類）
  • 北美過繼性細胞免疫療法市場依最終用途分類
  • 美國過繼性細胞免疫療法市場
  • 墨西哥過繼性細胞免疫療法市場
  • 加拿大過繼性細胞免疫療法市場

8. 歐洲過繼性細胞免疫療法市場

  • 概述
  • 歐洲過繼性細胞免疫療法市場（按類型分類）
  • 歐洲過繼性細胞免疫療法市場依最終用途分類
  • 德國過繼性細胞免疫療法市場
  • 法國過繼性細胞免疫療法市場
  • 西班牙過繼性細胞免疫療法市場
  • 義大利過繼性細胞免疫療法市場
  • 英國過繼性細胞免疫療法市場

9. 亞太地區過繼性細胞免疫療法市場

  • 概述
  • 亞太地區過繼細胞免疫療法市場（按類型分類）
  • 亞太地區過繼性細胞免疫療法市場（依最終用途分類）
  • 日本的過繼性細胞免疫療法市場
  • 印度過繼性細胞免疫療法市場
  • 中國細胞免疫療法市場
  • 韓國過繼性細胞免疫療法市場
  • 印尼過繼性細胞免疫療法市場

10. 世界其他地區（ROW）過繼性細胞免疫療法市場

  • 概述
  • ROW過繼細胞免疫療法市場按類型分類
  • ROW過繼細胞免疫療法市場以最終用途分類
  • 中東過繼性細胞免疫療法市場
  • 南美洲過繼性細胞免疫療法市場
  • 非洲過繼性細胞免疫療法市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市佔率分析

第12章：機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 按類型分類的成長機會
    • 按最終用途分類的成長機會
  • 全球過繼性細胞免疫療法市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 企業合併、協議、合作關係和合資企業

第13章：價值鏈中主要企業的概況

  • 競爭分析
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA

第14章附錄

  • 圖表清單
  • 表格列表
  • 分析方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於 Lucintel
  • 詢問

The future of the global adoptive cellular immunotherapy market looks promising with opportunities in the hospitals, cancer institutes, and others markets. The global adoptive cellular immunotherapy market is expected to grow with a CAGR of 23.1% from 2025 to 2031. The major drivers for this market are the growing cancer incidence drives demand for adoptive cellular immunotherapies., the advancements in car-t cell therapies enhance treatment efficacy and outcomes., and the high cost of adoptive cellular immunotherapies.

  • Lucintel forecasts that, within the type category, car t cell therapy is expected to witness the highest growth over the forecast period.
  • Within the application category, hospitals is expected to witness the highest growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Adoptive Cellular Immunotherapy Market

The market for adoptive cellular immunotherapy is witnessing several emerging trends that are reshaping the landscape. These trends reflect the growing potential of cellular therapies, improving patient outcomes, and expanding the scope of treatment.

  • Expansion to Solid Tumors: While CAR-T therapies have shown significant success in hematologic cancers, there is increasing focus on expanding their use to solid tumors. Advances in targeting mechanisms and modifications to CAR-T cells are making them more effective in treating cancers such as breast, lung, and ovarian cancers. This expansion represents a key trend in broadening the impact of adoptive cellular therapies.
  • Personalized and Precision Medicine: Adoptive cellular therapies are becoming an integral part of personalized medicine, where treatments are tailored to the individual genetic profiles of patients. The customization of therapies, including the development of patient-specific CAR-T cells, allows for more effective treatment and improved outcomes. This trend is revolutionizing cancer treatment by offering highly targeted, individualized options for patients.
  • Combination Therapies: There is growing interest in combining adoptive cellular immunotherapy with other treatment modalities, such as immune checkpoint inhibitors, chemotherapy, and targeted therapies. This strategy aims to enhance the immune response, overcome resistance mechanisms, and improve overall treatment efficacy. Combination therapies are expected to be a crucial driver in increasing the success rate of adoptive cellular immunotherapy for diverse cancers.
  • Regulatory Advancements and Approvals: Regulatory bodies in key markets like the U.S., China, and Japan are accelerating the approval of adoptive cellular immunotherapies, especially CAR-T therapies. Streamlined approval processes are reducing the time it takes for therapies to reach the market, facilitating quicker access for patients. This trend is crucial in accelerating the availability of these therapies ly and driving market growth.
  • Cost Reduction and Accessibility: The high cost of adoptive cellular immunotherapies has been a significant challenge. However, efforts to reduce manufacturing costs, improve scalability, and develop more affordable therapies are gaining momentum. As the cost of production decreases, accessibility will improve, making these advanced therapies available to a wider range of patients, particularly in developing countries like India and China.

The emerging trends in the adoptive cellular immunotherapy market, including the expansion to solid tumors, personalized medicine, combination therapies, regulatory advancements, and cost reduction, are reshaping the landscape of cancer treatment. These trends are enhancing the potential for adoptive cellular therapies to offer more effective, accessible, and targeted treatment options for cancer patients worldwide.

Recent Developments in the Adoptive Cellular Immunotherapy Market

The adoptive cellular immunotherapy market has seen significant advancements driven by technological innovations, new clinical trial results, and regulatory approvals. These developments are expanding the scope of adoptive cellular therapies and improving their effectiveness in treating various cancers.

  • FDA-Approved CAR-T Therapies: In the U.S., CAR-T therapies like Kymriah and Yescarta have been approved for the treatment of hematologic cancers such as leukemia and lymphoma. These approvals have paved the way for further expansion into solid tumors. The success of these therapies is driving the adoption of CAR-T cells, making them a key development in the immunotherapy market.
  • Technological Advancements in CAR-T Manufacturing: Innovations in CAR-T cell manufacturing are improving the scalability, cost-effectiveness, and speed of production. New automated technologies are helping reduce production costs, addressing one of the major challenges in adoptive cellular immunotherapy. As manufacturing becomes more efficient, the availability of CAR-T therapies will increase, making these treatments accessible to more patients worldwide.
  • Expansion of Clinical Trials: Clinical trials for adoptive cellular immunotherapies are rapidly expanding across various countries, including the U.S., China, and India. These trials are exploring new indications and combinations of therapies, allowing researchers to assess the efficacy of CAR-T and TIL therapies for a wider range of cancers. The increasing number of trials is a key factor driving market growth and innovation.
  • Regulatory Approvals in Emerging Markets: Countries like China and Japan are streamlining regulatory approval processes for adoptive cellular therapies, which is accelerating the market growth in these regions. Regulatory agencies are working closely with biotech companies to ensure the swift introduction of innovative therapies, improving access to CAR-T treatments and expanding the market ly.
  • Strategic Collaborations Between Biotech and Pharma: Collaborations between biotech firms and large pharmaceutical companies are helping accelerate the development and commercialization of adoptive cellular immunotherapies. These partnerships enable the sharing of resources, research, and expertise, which is crucial in advancing the clinical development of CAR-T and other cellular therapies. Such collaborations are playing a significant role in expanding the market.

Recent developments in the adoptive cellular immunotherapy market, including FDA approvals, technological innovations, expansion of clinical trials, regulatory approvals, and strategic collaborations, are driving the growth of the market. These advancements are bringing adoptive cellular therapies to more patients, with the potential to transform cancer treatment.

Strategic Growth Opportunities in the Adoptive Cellular Immunotherapy Market

The growing demand for adoptive cellular therapies presents significant strategic growth opportunities across various applications. These opportunities are expected to expand the market, enhance treatment options, and improve patient outcomes.

  • Expanding Indications for CAR-T Therapy: One of the major growth opportunities lies in expanding CAR-T therapies to treat solid tumors. Research is ongoing to adapt CAR-T cells to target cancers such as lung, breast, and pancreatic cancer. Success in this area could open up a vast new market for adoptive cellular immunotherapies, revolutionizing cancer treatment.
  • Combination of CAR-T with Other Immunotherapies: The combination of CAR-T therapies with other immunotherapies, such as checkpoint inhibitors or monoclonal antibodies, is a promising growth opportunity. This strategy can potentially enhance the immune response and improve overall treatment efficacy. By addressing treatment resistance and increasing tumor targeting, combination therapies could become a key development in the market.
  • Personalized Immunotherapy Approaches: Personalized medicine, including the use of patient-specific CAR-T therapies, presents significant growth potential. As advancements in genomics and cellular engineering continue, customized treatments tailored to individual patients' genetic profiles will become more prevalent, making adoptive cellular therapies more effective and offering better patient outcomes.
  • Regulatory Expediting in Emerging Markets: Emerging markets like China and India represent significant growth opportunities for adoptive cellular immunotherapy. As these countries streamline regulatory processes and expand access to innovative treatments, biotech companies can tap into large, underserved patient populations. This trend is expected to contribute significantly to market growth.
  • Manufacturing Cost Reduction: Reducing the cost of CAR-T and other cellular therapies is a critical growth opportunity. Innovations in manufacturing processes, such as automation and scale-up techniques, will drive down costs, making these therapies more affordable and accessible to a broader population. Lower costs will drive adoption and increase market size.

Strategic growth opportunities in the adoptive cellular immunotherapy market, including expanding indications, combination therapies, personalized medicine, regulatory progress in emerging markets, and manufacturing cost reduction, are poised to drive market expansion. These opportunities will help transform the landscape of cancer treatment, offering more accessible and effective options for patients ly.

Adoptive Cellular Immunotherapy Market Driver and Challenges

The adoptive cellular immunotherapy market is influenced by a range of technological, economic, and regulatory factors. These drivers and challenges impact the development, adoption, and scalability of adoptive cellular therapies. Understanding these elements is crucial for stakeholders seeking to navigate the complex landscape of adoptive immunotherapies, which show promising potential in treating cancer and other diseases but also face significant barriers.

The factors responsible for driving the Adoptive Cellular Immunotherapy Market include:

1. Advancements in Cell Therapy Technologies: Technological innovations in gene editing, stem cell research, and cell expansion techniques have led to more effective and scalable adoptive cellular therapies. These advancements enable higher success rates and improve patient outcomes, which drives growth in the market.

2. Increasing Cancer Incidence: The growing burden of cancer is a significant driver for adoptive cellular immunotherapies. As more patients seek advanced cancer treatments, the demand for immunotherapies like CAR-T and TIL therapies increases, expanding market opportunities.

3. Rising Investment and Funding in Immunotherapy: Increased investment from both public and private sectors into research, clinical trials, and production facilities is accelerating the development of adoptive cellular therapies. This influx of funding drives innovation and supports the commercialization of these therapies.

4. Shifting Focus Towards Personalized Medicine: There is a growing emphasis on personalized medicine, which tailors treatments to individual patients based on their genetic and molecular profiles. Adoptive cellular immunotherapies, such as CAR-T, are well-suited for this trend, further driving their market demand.

5. Regulatory Approvals and Market Expansion: The growing number of regulatory approvals for adoptive cellular immunotherapies, such as CAR-T, is opening new market avenues. These approvals make these therapies more accessible to patients and stimulate growth within the market.

Challenges in the Adoptive Cellular Immunotherapy Market are:

1. High Treatment Costs: The production of adoptive cellular therapies involves complex, personalized processes, leading to high treatment costs. These expenses can limit access to therapies, particularly in low-income regions, and hinder wider adoption, impacting overall market growth.

2. Manufacturing and Scalability Issues: The current manufacturing process for adoptive cellular therapies is labor-intensive, time-consuming, and difficult to scale. This limits the ability to meet growing patient demand and presents challenges to market expansion.

3. Safety and Efficacy Concerns: Despite positive results, the safety and efficacy of adoptive cellular therapies can vary. Adverse effects, such as cytokine release syndrome and neurotoxicity, as well as inconsistent outcomes, remain a challenge, which can undermine patient confidence and slow market adoption.

The adoptive cellular immunotherapy market is shaped by advancements in technology, growing cancer rates, and increasing funding for research. However, high treatment costs, manufacturing challenges, and concerns about safety and efficacy present significant obstacles. Balancing these drivers and challenges will be key to determining the market's future success and its potential for widespread adoption.

List of Adoptive Cellular Immunotherapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adoptive cellular immunotherapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adoptive cellular immunotherapy companies profiled in this report include-

  • Bristol-Myers Squibb Company
  • Novartis AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA

Adoptive Cellular Immunotherapy Market by Segment

The study includes a forecast for the global adoptive cellular immunotherapy market by type, end use, and region.

Adoptive Cellular Immunotherapy Market by Type [Value from 2019 to 2031]:

  • Car T Cell Therapy
  • Nk Cell Therapy
  • Til Therapy
  • Others

Adoptive Cellular Immunotherapy Market by End Use [Value from 2019 to 2031]:

  • Hospitals
  • Cancer Institutes
  • Others

Adoptive Cellular Immunotherapy Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Adoptive Cellular Immunotherapy Market

The market for adoptive cellular immunotherapy is experiencing rapid growth as this innovative approach continues to transform cancer treatment. By harnessing the power of the immune system, adoptive cellular therapies such as CAR-T and TIL therapies are gaining attention in the fight against various cancers. The United States, China, Germany, India, and Japan are leading advancements in research, clinical trials, and regulatory approvals, shaping the landscape for these therapies.

  • United States: The U.S. remains a leader in adoptive cellular immunotherapy, with CAR-T cell therapies such as Kymriah and Yescarta being FDA-approved for multiple cancers. Ongoing research focuses on overcoming challenges like treatment resistance and expanding applications beyond blood cancers to solid tumors. The high demand for personalized therapies and strong financial investment from biotech and pharmaceutical companies are driving the rapid development of these therapies.
  • China: China is making significant strides in adoptive cellular immunotherapy, especially in the development of CAR-T therapies. Chinese companies are leading in the commercialization of cost-effective therapies for blood cancers and have started conducting clinical trials for solid tumors. Regulatory authorities in China are accelerating approval processes, making the country an emerging market for CAR-T cell therapies, and they are looking to expand to more affordable options for patients.
  • Germany: Germany is at the forefront of adoptive cellular immunotherapy research in Europe. Strong collaborations between academic institutions and pharmaceutical companies have advanced CAR-T and TIL (Tumor-Infiltrating Lymphocyte) therapies, particularly for hematologic cancers. The country's supportive regulatory framework and focus on personalized medicine are accelerating the development of these therapies, with increasing participation in clinical trials and ongoing research to enhance efficacy and minimize side effects.
  • India: India's adoptive cellular immunotherapy market is gaining momentum, especially with an increase in clinical trials for CAR-T therapies. Research institutions and biotech companies are partnering with international firms to expand access to innovative therapies. With a large population of cancer patients, particularly those with blood cancers, India is becoming a significant player in the adoption of CAR-T therapies, though affordability and accessibility remain key challenges.
  • Japan: Japan has been advancing in adoptive cellular immunotherapy, with several clinical trials focused on CAR-T and TIL therapies. Japan's efficient healthcare system and regulatory processes are conducive to the approval and rapid adoption of these therapies. Additionally, collaborations with international biotech companies are facilitating the development of new treatments. Japan is particularly focused on expanding these therapies to treat a wider range of cancers, including solid tumors.

Features of the Global Adoptive Cellular Immunotherapy Market

  • Market Size Estimates: Adoptive cellular immunotherapy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Adoptive cellular immunotherapy market size by type, end use, and region in terms of value ($B).
  • Regional Analysis: Adoptive cellular immunotherapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different type, end use, and regions for the adoptive cellular immunotherapy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adoptive cellular immunotherapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the adoptive cellular immunotherapy market by type (car t cell therapy, nk cell therapy, til therapy, and others), end use (hospitals, cancer institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Adoptive Cellular Immunotherapy Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 CAR T Cell Therapy: Trends and Forecast (2019-2031)
  • 4.4 NK Cell Therapy: Trends and Forecast (2019-2031)
  • 4.5 TIL Therapy: Trends and Forecast (2019-2031)
  • 4.6 Others: Trends and Forecast (2019-2031)

5. Global Adoptive Cellular Immunotherapy Market by End Use

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by End Use
  • 5.3 Hospitals: Trends and Forecast (2019-2031)
  • 5.4 Cancer Institutes: Trends and Forecast (2019-2031)
  • 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Adoptive Cellular Immunotherapy Market by Region

7. North American Adoptive Cellular Immunotherapy Market

  • 7.1 Overview
  • 7.2 North American Adoptive Cellular Immunotherapy Market by type
  • 7.3 North American Adoptive Cellular Immunotherapy Market by end use
  • 7.4 United States Adoptive Cellular Immunotherapy Market
  • 7.5 Mexican Adoptive Cellular Immunotherapy Market
  • 7.6 Canadian Adoptive Cellular Immunotherapy Market

8. European Adoptive Cellular Immunotherapy Market

  • 8.1 Overview
  • 8.2 European Adoptive Cellular Immunotherapy Market by type
  • 8.3 European Adoptive Cellular Immunotherapy Market by end use
  • 8.4 German Adoptive Cellular Immunotherapy Market
  • 8.5 French Adoptive Cellular Immunotherapy Market
  • 8.6 Spanish Adoptive Cellular Immunotherapy Market
  • 8.7 Italian Adoptive Cellular Immunotherapy Market
  • 8.8 United Kingdom Adoptive Cellular Immunotherapy Market

9. APAC Adoptive Cellular Immunotherapy Market

  • 9.1 Overview
  • 9.2 APAC Adoptive Cellular Immunotherapy Market by type
  • 9.3 APAC Adoptive Cellular Immunotherapy Market by end use
  • 9.4 Japanese Adoptive Cellular Immunotherapy Market
  • 9.5 Indian Adoptive Cellular Immunotherapy Market
  • 9.6 Chinese Adoptive Cellular Immunotherapy Market
  • 9.7 South Korean Adoptive Cellular Immunotherapy Market
  • 9.8 Indonesian Adoptive Cellular Immunotherapy Market

10. ROW Adoptive Cellular Immunotherapy Market

  • 10.1 Overview
  • 10.2 ROW Adoptive Cellular Immunotherapy Market by type
  • 10.3 ROW Adoptive Cellular Immunotherapy Market by end use
  • 10.4 Middle Eastern Adoptive Cellular Immunotherapy Market
  • 10.5 South American Adoptive Cellular Immunotherapy Market
  • 10.6 African Adoptive Cellular Immunotherapy Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by End Use
  • 12.3 Emerging Trends in the Global Adoptive Cellular Immunotherapy Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Bristol-Myers Squibb Company
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Novartis AG
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Gilead Sciences Inc.
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 F. Hoffmann-La Roche Ltd
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Merck KGaA
    • Company Overview
    • Adoptive Cellular Immunotherapy Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Adoptive Cellular Immunotherapy Market
  • Figure 2.1: Usage of Adoptive Cellular Immunotherapy Market
  • Figure 2.2: Classification of the Global Adoptive Cellular Immunotherapy Market
  • Figure 2.3: Supply Chain of the Global Adoptive Cellular Immunotherapy Market
  • Figure 3.1: Driver and Challenges of the Adoptive Cellular Immunotherapy Market
  • Figure 3.2: PESTLE Analysis
  • Figure 3.3: Patent Analysis
  • Figure 3.4: Regulatory Environment
  • Figure 4.1: Global Adoptive Cellular Immunotherapy Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Adoptive Cellular Immunotherapy Market ($B) by Type
  • Figure 4.3: Forecast for the Global Adoptive Cellular Immunotherapy Market ($B) by Type
  • Figure 4.4: Trends and Forecast for CAR T Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 4.5: Trends and Forecast for NK Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 4.6: Trends and Forecast for TIL Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Others in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 5.1: Global Adoptive Cellular Immunotherapy Market by End Use in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Adoptive Cellular Immunotherapy Market ($B) by End Use
  • Figure 5.3: Forecast for the Global Adoptive Cellular Immunotherapy Market ($B) by End Use
  • Figure 5.4: Trends and Forecast for Hospitals in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Cancer Institutes in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Others in the Global Adoptive Cellular Immunotherapy Market (2019-2031)
  • Figure 6.1: Trends of the Global Adoptive Cellular Immunotherapy Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Adoptive Cellular Immunotherapy Market ($B) by Region (2025-2031)
  • Figure 7.1: North American Adoptive Cellular Immunotherapy Market by type in 2019, 2024, and 2031
  • Figure 7.2: Trends of the North American Adoptive Cellular Immunotherapy Market ($B) by type (2019-2024)
  • Figure 7.3: Forecast for the North American Adoptive Cellular Immunotherapy Market ($B) by type (2025-2031)
  • Figure 7.4: North American Adoptive Cellular Immunotherapy Market by end use in 2019, 2024, and 2031
  • Figure 7.5: Trends of the North American Adoptive Cellular Immunotherapy Market ($B) by end use (2019-2024)
  • Figure 7.6: Forecast for the North American Adoptive Cellular Immunotherapy Market ($B) by end use (2025-2031)
  • Figure 7.7: Trends and Forecast for the United States Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 7.8: Trends and Forecast for the Mexican Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Canadian Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.1: European Adoptive Cellular Immunotherapy Market by type in 2019, 2024, and 2031
  • Figure 8.2: Trends of the European Adoptive Cellular Immunotherapy Market ($B) by type (2019-2024)
  • Figure 8.3: Forecast for the European Adoptive Cellular Immunotherapy Market ($B) by type (2025-2031)
  • Figure 8.4: European Adoptive Cellular Immunotherapy Market by end use in 2019, 2024, and 2031
  • Figure 8.5: Trends of the European Adoptive Cellular Immunotherapy Market ($B) by end use (2019-2024)
  • Figure 8.6: Forecast for the European Adoptive Cellular Immunotherapy Market ($B) by end use (2025-2031)
  • Figure 8.7: Trends and Forecast for the German Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.8: Trends and Forecast for the French Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the Spanish Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Italian Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the United Kingdom Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.1: APAC Adoptive Cellular Immunotherapy Market by type in 2019, 2024, and 2031
  • Figure 9.2: Trends of the APAC Adoptive Cellular Immunotherapy Market ($B) by type (2019-2024)
  • Figure 9.3: Forecast for the APAC Adoptive Cellular Immunotherapy Market ($B) by type (2025-2031)
  • Figure 9.4: APAC Adoptive Cellular Immunotherapy Market by end use in 2019, 2024, and 2031
  • Figure 9.5: Trends of the APAC Adoptive Cellular Immunotherapy Market ($B) by end use (2019-2024)
  • Figure 9.6: Forecast for the APAC Adoptive Cellular Immunotherapy Market ($B) by end use (2025-2031)
  • Figure 9.7: Trends and Forecast for the Japanese Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.8: Trends and Forecast for the Indian Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Chinese Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the South Korean Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the Indonesian Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 10.1: ROW Adoptive Cellular Immunotherapy Market by type in 2019, 2024, and 2031
  • Figure 10.2: Trends of the ROW Adoptive Cellular Immunotherapy Market ($B) by type (2019-2024)
  • Figure 10.3: Forecast for the ROW Adoptive Cellular Immunotherapy Market ($B) by type (2025-2031)
  • Figure 10.4: ROW Adoptive Cellular Immunotherapy Market by end use in 2019, 2024, and 2031
  • Figure 10.5: Trends of the ROW Adoptive Cellular Immunotherapy Market ($B) by end use (2019-2024)
  • Figure 10.6: Forecast for the ROW Adoptive Cellular Immunotherapy Market ($B) by end use (2025-2031)
  • Figure 10.7: Trends and Forecast for the Middle Eastern Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 10.8: Trends and Forecast for the South American Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the African Adoptive Cellular Immunotherapy Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Adoptive Cellular Immunotherapy Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Adoptive Cellular Immunotherapy Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Adoptive Cellular Immunotherapy Market by Type
  • Figure 12.2: Growth Opportunities for the Global Adoptive Cellular Immunotherapy Market by End Use
  • Figure 12.3: Growth Opportunities for the Global Adoptive Cellular Immunotherapy Market by Region
  • Figure 12.4: Emerging Trends in the Global Adoptive Cellular Immunotherapy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Adoptive Cellular Immunotherapy Market by Type and End Use
  • Table 1.2: Attractiveness Analysis for the Adoptive Cellular Immunotherapy Market by Region
  • Table 1.3: Global Adoptive Cellular Immunotherapy Market Parameters and Attributes
  • Table 3.1: Trends of the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 3.2: Forecast for the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Adoptive Cellular Immunotherapy Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.4: Trends of CAR T Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.5: Forecast for CAR T Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.6: Trends of NK Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.7: Forecast for NK Cell Therapy in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.8: Trends of TIL Therapy in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.9: Forecast for TIL Therapy in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 4.10: Trends of Others in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 4.11: Forecast for Others in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Adoptive Cellular Immunotherapy Market by End Use
  • Table 5.2: Market Size and CAGR of Various End Use in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various End Use in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 5.4: Trends of Hospitals in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 5.5: Forecast for Hospitals in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 5.6: Trends of Cancer Institutes in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 5.7: Forecast for Cancer Institutes in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 5.8: Trends of Others in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 5.9: Forecast for Others in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 7.1: Trends of the North American Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 7.2: Forecast for the North American Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various type in the North American Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various type in the North American Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various end use in the North American Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various end use in the North American Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.1: Trends of the European Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 8.2: Forecast for the European Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various type in the European Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various type in the European Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various end use in the European Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various end use in the European Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.1: Trends of the APAC Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 9.2: Forecast for the APAC Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various type in the APAC Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various type in the APAC Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various end use in the APAC Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various end use in the APAC Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 10.1: Trends of the ROW Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 10.2: Forecast for the ROW Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various type in the ROW Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various type in the ROW Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various end use in the ROW Adoptive Cellular Immunotherapy Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various end use in the ROW Adoptive Cellular Immunotherapy Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Adoptive Cellular Immunotherapy Market (2019-2031)
  • Table 11.1: Product Mapping of Adoptive Cellular Immunotherapy Suppliers Based on Segments
  • Table 11.2: Operational Integration of Adoptive Cellular Immunotherapy Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Adoptive Cellular Immunotherapy Revenue
  • Table 12.1: New Product Launches by Major Adoptive Cellular Immunotherapy Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Adoptive Cellular Immunotherapy Market